The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wouldn't worry about the black box warnings, the anti-TNF drugs all still have those and are huge blockbusters, it is accepted with that level of serious disease and not many options available
I believe the day that is secured will probably be the day we get bought out. I can't see to many majors wanting to battle it out for too long on such a lucrative market. The silence is deafening and it can only be a matter of time.
Thanks afham, will be a good day when thats secured and i trust JR has done the business.
Not yet Coldfish- that's what we are all waiting for and the crux of the dismay on here at present.
Aye Potnak, I read that this morning too- as Citizen says it's a game-changer. Remember in last years finals one of the deal outlined was Xeljanz® tofacitinib (JAK1/JAK3 inhibitor) - approved for rheumatoid and psoriatic arthritis and ulcerative colitis, with 2017 sales of $1.35Bn and $1.8bn in 2018, despite black box warnings for serious infections and lymphoma). Pfizer were funding the studies and we were smashing Tofa even with a low dose, when we upped the dose to one which Tofa could not reach it showed trace after 30days (i.e. no arthritis, cured). so the market is vast for RA as this Abbvie approval shows and I believe we have promise as it wasn't long ago the FDA shouldered Tofa. Additionally we also have Tyk2 Cancer which I still believe is one of the main triggers for the Celgene/BMS deal and why Ortezla which was generating $1.2bn per year was dropped to secure this.
Good to see, TYK2 really is the game changer for us I feel:
As an addition, I stumbled across some early data on (potentially) JAK/TYK2 inhibition being used via the inhaled route and its efficacy to inhibit airway inflammation. - I appreciate we are working towards the oral route, but interesting nonetheless, and something I hadn't associated with the application of our or our competitors TYK2 offerings.
Musings of a fellow Sareum holder... all the best.
Yes.....but does anyone have any update on the tyk2 patent?
Sorry, been off for a while so missed any news fron the meeting?
To slightly contradict my post on this thread. Abbvie has gained FDA approval for an Oral JAK1 for Rheumatoid Arthritis with a potential $2.4 billion in annual sales by 2024. https://endpts.com/abbvie-gets-its-fda-ok-for-jak-inhibitor-upadacitinib-but-dont-look-for-this-one-to-hit-execs-lofty-expectations/
Sooner we get our TYK2 into trials the better.
Hi Potnak and Krone ,
Krone is correct in saying that it was the BOD who posted the comparisons for valuations and it is also fair to say that they would have been advised on this strategy. I believe that in life, everything has a reason and purpose - so what was the reason and purpose for SAR to provide deal valuations/comparisons?? Therefore, they have to take their share of responsibility of feeding the flames on speculation.
IMHO and as I've eluded to many times - its only upside from anywhere sub 1p, timescales - very difficult to predict but as we all know the biotech/pharmas always surprise the market.
Whats the latest on the tyk2 patent...anyone?
Hi all. Think what annoys us all genuine investors is lack of news ..... chk1 one looking good and believe will get us to 6p ? Correct me if wrong. Thoth views I have always appreciated as he finds genuine information ....and then uses that to get to his valuation. He thinks chk1 20p ....am now not so sure and am like you potnak. ...being more conservative. Tyk2 as you state has not been in trials and not proved anything. ..I would happily take 8 to 10p for the lot in the next year. All views appreciated.
If I remember rightly, they've only done it once and it was to placate the investors. Thoth has been saying 28p sinch 2016 at least. I have have a lot of respect for Thoth and his knowledge, sometimes disagree with his timescales and valuations but others have probably invested and the back of what he says and now they want their 28p.
Potnak - my point is that Sareum are themselves fuelling the speculation.
Krone - bio bucks deals. Go back and check how much has actually been pain. Either that it the valuations are for compounds that are 5 years further down the line than ours. Not saying it won't happen, it plainly could. Are you willing to wait another 5 years for it? I'm comfortable with my investment but I have more realistic expectations. Both timescale and potential profit.
The scale of the deals and sales delivered/forecast for these candidates and products targeting TYK2 and related JAK family members gives Sareum confidence in the exciting, high value market opportunity for SDC-1801
Potnak - In fairness, responsibility for the speculation regarding potential values has been fuelled at least in part by Sareum - http://www.sareum.com/files/2215/3838/2124/Sareum_2018_FY_Results_.pdf
TD-1473 (a pan-JAK inhibitor) – licensed by Janssen from Theravance (2018) at the end of Phase 1 studies for $100M cash up-front, up to $900M in milestone payments, plus royalties*
? Filgotinib (JAK1 inhibitor) – licensed by Gilead from Galapagos (2015) at the end of Phase 2 trials for $300M cash and $425M equity investment up-front, up to $1,350M in milestone payments, plus 20%+ royalties*
? Undisclosed TYK2 inhibitor (plus other assets) – Celgene formed an alliance with Nimbus Therapeutics (2017) in preclinical stage for undisclosed up-front and milestone payments
Approved products targeting the JAK family with blockbuster sales potential, despite warnings based on side effects related to JAK2/JAK3 activity, include:
? Xeljanz® tofacitinib (Pfizer) (JAK1/JAK3 inhibitor) - approved for rheumatoid and psoriatic arthritis and ulcerative colitis, with 2017 sales of $1.35Bn*, despite black box warnings for serious infections and lymphoma
? Olumiant® baricitinib (Eli Lilly) (JAK1/JAK2 inhibitor) – approved from rheumatoid arthritis, with expected peak sales of approximately $1Bn*, but with black box warnings for serious infections, lymphoma and thrombosis
? Jakafi® ruxolitinib (Incyte/Novartis) – approved for myelofibrosis and polycythemia vera (a type of blood cancer) with 2017 sales of $1.1Bn* despite warnings of infections and blood cell counts
The scale of the deals and sales delivered/forecast for these candidates and products targeting TYK2 and related JAK family members gives Sareum confidence in the exciting, high value market opportunity for SDC-1801
There is a reason no context was given with the Sierra update and we never get get any context when an advisor is changed. No company does that. We can only speculate. We've just had a fundraise, so it probably isn't that. Looking at the strand website it's clear they operate in a different space to WH. Mainly MA and advising activist shareholders. For what its worth I think its the latter. I think WH have been sacked off for advising to keep the shareholders in the dark and its backfired. The fact that strand are on record, saying how boards and forums shouldn't dictate news flow seals it for me IMO this is a direct result of Thoth threatening to call an EGM. I expect to get more updates from now on. They won't tell us anything of course, just enough get us to put the pitchforks down. Also this board and others have to carry some of the blame. People need to stop throwing the billion pound valuations around or at least be honest in the risk of hanging around for those valuations. One drug is doing ok in trials and the others aren't even in P1 trials yet. Remember, these valuations didn't come from the company. They came from this board and the company is being called out to deliver on something they never said they would. I honestly believe our share of CHK1 will he worth £200 million when it gets into P3 proper. Tyk2 isn't worth anything until can get into clinic. 18 to 24 month timescale for 5p there.
Or just corporate ****.
We partner with our clients to deliver solutions consistent with their strategies.
Using our focused expertise, we are able to minimise the risks inherent in complex transactions in order to structure the best deal for our clients. We seek to tailor each transaction to the specific needs of our clients, recognising that the “one size fits all” model does not maximise value or deliverability.
Effective planning significantly improves transaction processes – ensuring that the end result is consistent with the wider corporate strategy.
Drawing on our executive team’s considerable experience across a significant range of sectors, geographies and transaction types, Strand Hanson is focused on delivering bespoke, strategic and timely advice.
https://strandhanson.co.uk/about/approach-and-culture/
https://www.whirelandplc.com
I don’t agree with that Thoth as in past experience if the Nomad is unhappy then don’t they normally resign position and a company has a number of days to find another, I think Sareum need something new that WH Ireland does not offer as a service looking at the website on services there is a distinct difference between them both imo!
As shareholders we own all the patents intellectual property. If the officers who we appoint care to also invest they will too. If they dont we can appoint new officers. If you are a shareholder you have rights. If not. Not so much.
It is also possible that sar were dumped by the previous adviser after all they recommended their clients to buy. Based on what the bod assured them. To see it 25% underwater a week later based on info the bod possibly had I'd dump a client like that straight away imho Dyor etc. They had a reputation for probity and straight talking. Kicking aurora into the long grass for 5 years price action showing actors are aware of placings. Have rather squandered that reputation.
If you need tools to get the job done you have to have these services, we have just had a fund raise and I guess some dialogue from management would do wonders for long terms investors so could be something necessary in facilitating/advising/advancing, I feel it’s a positive step!
Good morning Aber, I have been with SAR forever like many others on here. I am getting the impression that they are working on something in the background. It would appear, IMHO, that as they are working through a deal, line by line, when they come across an issue or problem they are correcting it immediately. The involvement of the new NEDs, the additional disclosure from one of the NEDs past associates and now the changing of the Nomad. I take a lot of faith from Tim’s statement about significant value for shareholders in next 12 months, and that statement came before the fund raising, for a relatively low amount. You mention the monthly burn, well 700k about covers the burn for 12 months. I also believe that Sar were aware of the Sierra issue months ago and that is why they went for more cash with the placing.
I understand people’s frustrations on here, it has been like that for the 10 years I have been here, but I believe Tim to be honest, crap at the business side, but honest and I for one will be giving him the remaining 10 months to bring home the bacon, plus as many as possible should attend the AGM. Thanks. GLA